FDA approves Novavax's COVID-19 vaccine for adults 65+ or 12-64 with health conditions

From Yahoo Finance: 2025-05-18 20:53:00

The FDA has fully approved Novavax, Inc. (NVAX)’s COVID-19 vaccine, but with restrictions. The vaccine is now only approved for adults 65 and older, or for those aged 12-64 with underlying health conditions. Novavax’s vaccine is protein-based, offering an alternative to mRNA-based vaccines. The company reported strong earnings in Q1 2025, with revenue of $666.6 million, a 610.3% growth from last year. EPS of $2.93 beat estimates. Despite NVAX’s potential, some AI stocks may offer higher returns with limited risk. No promotional content was included in the news article.



Read more at Yahoo Finance: FDA Clears Novavax, Inc. (NVAX)’s COVID-19 Vaccine with Usage Restrictions